Propanc Biopharma Reports $54.9M Loss Amid Rising Expenses, Faces Financial Struggles Ahead

Propanc Biopharma, Inc. (OTCMKTS: PPCB) has reported its financial results for the nine months ended March 31, 2025. The company focuses on developing novel cancer therapies, primarily targeting pancreatic, ovarian, and colorectal cancer with its lead candidate, PRP.

Key Highlights from Q3 2025:

• Revenue: $0 (no sales generated during the period)
• Net Loss: $54.9 million, compared to a loss of $1.5 million for the same period last year.
• Administration Expenses: Increased significantly to $53.4 million (up from $1.1 million), primarily due to stock-based compensation expenses.
• Research and Development Expenses: Decreased to $170,199 from $195,712 year-over-year.
• Interest Expense: Reduced to $309,215 from $575,837, reflecting lower amortization of debt discounts.
• Loss on Extinguishment of Debt: Notable loss recorded totaling $213,752 related to several debt exchanges.
• CASH position: Cash stands at $50,760 compared to $21,085 at June 30, 2024.

Positive Aspects:

• The recent issuance of stock for debt exchanges indicates some confidence from creditors, as it reflects an agreed restructuring approach with stakeholders.
• Successful filing of patents and ongoing R&D collaboration with academic institutions shelters future growth opportunities.
• Significant liquidity provided through financing activities totaling $483,000 during the last nine months.

Negative Aspects:

• The net loss has surged dramatically year-over-year, primarily due to increased administrative expenses linked to stock options and consulting costs.
• Total liabilities rose to $4.4 million, up from $3.9 million, indicating mounting financial stress.
• Current liabilities exceeded cash available significantly, raising concerns about operational sustainability and future funding needs.
• Pending defaults on multiple loans, including convertible notes, could further hinder liquidity and operational viability.

The company's stated goal is to enhance its financial health through further capital raises and potential product launches, but various operational challenges and substantial accumulated deficits raise alarm about its ability to continue as a going concern.